Upadacitinib for the Treatment of Alopecia Areata and Severe Atopic Dermatitis in a Pediatric Patient: A Case Report
January 2022
in “
SAGE open medical case reports
”
TLDR Upadacitinib successfully treated a child's severe skin and hair loss issues.
This case report details the first successful use of the Janus kinase 1 inhibitor upadacitinib to treat alopecia areata and severe atopic dermatitis in a pediatric patient. The patient showed minimal response to topical corticosteroids and spironolactone, but significant improvements in hair growth on the scalp and body were observed after just 6 weeks of upadacitinib treatment.